logo

Aim Immunotech Inc. (AIM)



Trade AIM now with
  Date
  Headline
8/15/2019 6:48:16 AM Hemispherx Biopharma Q2 Net Loss From Cont Ops $2.03 Mln Or $1.07 Per Share
5/31/2019 10:41:19 AM Hemispherx Biopharma Approves 1-for-44 Reverse Stock Split
1/2/2019 8:32:32 AM Hemispherx Announces Advancement In Expanded Access Program For Ampligen
12/26/2018 8:31:57 AM Hemispherx Says Works With Apple, Affected Parties For Solution To Correct Apple IOS12 Stocks Application Misinformation
12/19/2018 8:33:32 AM Hemispherx Biopharma Reports First Large Ampligen Shipment To Clinical Site For Use In US Expanded Access Program
12/12/2018 8:33:01 AM Hemispherx Biopharma Issues Letter To Stockholders
11/15/2018 9:05:33 AM Hemispherx Biopharma Q3 Net Loss From Cont Ops $3.078 Mln Or $0.07 Per Share
10/22/2018 8:32:00 AM Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy For Multiple Cancers In Letter To Stockholders
10/10/2018 8:34:35 AM Hemispherx Biopharma Signs Clinical Trial Agreement With Roswell Park Comprehensive Cancer Center To Study Ampligen
9/18/2018 8:31:21 AM Hemispherx Biopharma To Distribute Second Lot Of Ampligen For Multiple Indications In Argentina, US And Europe
8/15/2018 8:40:32 AM Hemispherx Biopharma 6-month Net Loss $5.1 Mln Or $0.13/shr Vs. Net Loss $5.0 Mln Or $0.19/shr Last Year
6/27/2018 8:34:02 AM Hemispherx Biopharma Says Immediate Expansion Of Treatment Protocol/Expanded Access Programs For ME/CFS In U.S.